StonvexLoading…
StonvexStonvexStonvexCore line items from TRS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $645.72M | $630.80M | $652.15M | $883.83M |
Operating Income | $41.30M | $15.17M | $50.66M | $99.06M |
Net Income | $120.14M | $24.25M | $40.36M | $66.17M |
EPS (Diluted) | $2.95 | $0.60 | $0.97 | $1.56 |
Total Assets | $1.49B | $1.32B | $1.34B | $1.30B |
Total Liabilities | $779.49M | $656.88M | $658.71M | $653.17M |
Cash & Equivalents | $30.02M | $23.07M | $34.89M | $112.09M |
Free Cash Flow OCF − CapEx | $69.10M | $12.82M | $33.97M | $26.61M |
Shares Outstanding | 37.63M | 40.57M | 41.20M | 41.72M |